TREM2: friend or foe in glioma?

Authors

Mekenzie M Peshoff, Dolores Hambardzumyan, Long-Jun Wu

Published in

Brain : a journal of neurology. Oct 27, 2026. Epub Oct 27, 2026.

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) is a neuroimmune signaling hub involved in key cellular processes including microglial phagocytosis, chemotaxis, and inflammation. Dysregulation of TREM2 has been implicated in a variety of diseases, most notably in the innate immune response to neurodegenerative disorders and cancer. The TREM2 pathway plays a significant role in governing microglia phenotypic transitions in Alzheimer's disease, as well as in regulating tumor-associated macrophages' ability to modulate cytotoxic activity. However, TREM2's role can be dependent on experimental parameters and disease contexts. Due to its intricate involvement in related disorders and the myeloid-dominated microenvironment in brain tumors, TREM2 has emerged as a vital player to better understand neuroimmune contributions to central nervous system malignancies. This review critically evaluates TREM2's controversial function in gliomas, analyzes experimental and biological variables that may underlie divergent findings, and outlines important considerations for future investigations.

PMID:
42934953
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.